7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Soluble α-synuclein aggregates varying in size, structure, and morphology have been closely linked to neuronal death in Parkinson’s disease. However, the heterogeneity of different co-existing aggregate species makes it hard to isolate and study their individual toxic properties. Here, we show a reliable non-perturbative method to separate a heterogeneous mixture of protein aggregates by size. We find that aggregates of wild-type α-synuclein smaller than 200 nm in length, formed during an in vitro aggregation reaction, cause inflammation and permeabilization of single-liposome membranes and that larger aggregates are less toxic. Studying soluble aggregates extracted from post-mortem human brains also reveals that these aggregates are similar in size and structure to the smaller aggregates formed in aggregation reactions in the test tube. Furthermore, we find that the soluble aggregates present in Parkinson’s disease brains are smaller, largely less than 100 nm, and more inflammatory compared to the larger aggregates present in control brains. This study suggests that the small non-fibrillar α-synuclein aggregates are the critical species driving neuroinflammation and disease progression.

          Abstract

          α-synuclein aggregates cause neuronal damage, but their heterogeneity complicates studying their toxic properties. Here, the authors analyze α-synuclein aggregates in vitro and study post-mortem brain samples, providing evidence that small aggregates are the main culprit for neuronal death in Parkinson’s disease.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: not found

          Parkinson disease

          Parkinson disease is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age. Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease. Multiple other cell types throughout the central and peripheral autonomic nervous system are also involved, probably from early disease onwards. Although clinical diagnosis relies on the presence of bradykinesia and other cardinal motor features, Parkinson disease is associated with many non-motor symptoms that add to overall disability. The underlying molecular pathogenesis involves multiple pathways and mechanisms: α-synuclein proteostasis, mitochondrial function, oxidative stress, calcium homeostasis, axonal transport and neuroinflammation. Recent research into diagnostic biomarkers has taken advantage of neuroimaging in which several modalities, including PET, single-photon emission CT (SPECT) and novel MRI techniques, have been shown to aid early and differential diagnosis. Treatment of Parkinson disease is anchored on pharmacological substitution of striatal dopamine, in addition to non-dopaminergic approaches to address both motor and non-motor symptoms and deep brain stimulation for those developing intractable L-DOPA-related motor complications. Experimental therapies have tried to restore striatal dopamine by gene-based and cell-based approaches, and most recently, aggregation and cellular transport of α-synuclein have become therapeutic targets. One of the greatest current challenges is to identify markers for prodromal disease stages, which would allow novel disease-modifying therapies to be started earlier.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Staging of brain pathology related to sporadic Parkinson’s disease

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Stages in the development of Parkinson's disease-related pathology.

              The synucleinopathy, idiopathic Parkinson's disease, is a multisystem disorder that involves only a few predisposed nerve cell types in specific regions of the human nervous system. The intracerebral formation of abnormal proteinaceous Lewy bodies and Lewy neurites begins at defined induction sites and advances in a topographically predictable sequence. As the disease progresses, components of the autonomic, limbic, and somatomotor systems become particularly badly damaged. During presymptomatic stages 1-2, inclusion body pathology is confined to the medulla oblongata/pontine tegmentum and olfactory bulb/anterior olfactory nucleus. In stages 3-4, the substantia nigra and other nuclear grays of the midbrain and forebrain become the focus of initially slight and, then, severe pathological changes. At this point, most individuals probably cross the threshold to the symptomatic phase of the illness. In the end-stages 5-6, the process enters the mature neocortex, and the disease manifests itself in all of its clinical dimensions.
                Bookmark

                Author and article information

                Contributors
                dk10012@cam.ac.uk
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                20 September 2022
                20 September 2022
                2022
                : 13
                : 5512
                Affiliations
                [1 ]GRID grid.5335.0, ISNI 0000000121885934, Yusuf Hamied Department of Chemistry, , University of Cambridge, ; Lensfield Road, Cambridge, UK
                [2 ]GRID grid.5335.0, ISNI 0000000121885934, UK Dementia Research Institute, , University of Cambridge, ; Cambridge, UK
                [3 ]GRID grid.4818.5, ISNI 0000 0001 0791 5666, Laboratory of Organic Chemistry, , Wageningen University and Research, ; Wageningen, Netherlands
                [4 ]GRID grid.4818.5, ISNI 0000 0001 0791 5666, Physical Chemistry and Soft Matter, , Wageningen University and Research, ; Wageningen, Netherlands
                [5 ]GRID grid.5335.0, ISNI 0000000121885934, John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, , University of Cambridge, ; Cambridge, UK
                [6 ]GRID grid.5335.0, ISNI 0000000121885934, Molecular Imaging Chemistry Laboratory, Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, , University of Cambridge, ; Cambridge, UK
                [7 ]GRID grid.11835.3e, ISNI 0000 0004 1936 9262, Sheffield Institute for Translational Neuroscience, , University of Sheffield, ; Sheffield, UK
                Author information
                http://orcid.org/0000-0002-3853-664X
                http://orcid.org/0000-0002-9662-8454
                http://orcid.org/0000-0002-5977-9691
                http://orcid.org/0000-0003-0571-5892
                http://orcid.org/0000-0001-7408-2342
                http://orcid.org/0000-0003-1675-0773
                http://orcid.org/0000-0002-7879-0140
                http://orcid.org/0000-0002-3616-1610
                http://orcid.org/0000-0002-1232-1907
                http://orcid.org/0000-0002-2648-9743
                http://orcid.org/0000-0001-7116-6954
                Article
                33252
                10.1038/s41467-022-33252-6
                9489799
                36127374
                dc1283e4-d825-41a7-996c-f72032e05f7b
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 3 January 2022
                : 8 September 2022
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100000304, Parkinson's UK;
                Award ID: G-1901
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100000288, Royal Society;
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Uncategorized
                parkinson's disease,protein aggregation,intrinsically disordered proteins
                Uncategorized
                parkinson's disease, protein aggregation, intrinsically disordered proteins

                Comments

                Comment on this article